Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Br J Cancer
    August 2021
  1. MULLEE A, Dimou N, Allen N, O'Mara T, et al
    Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses.
    Br J Cancer. 2021 Aug 6. pii: 10.1038/s41416-021-01518.
    >> Share

    June 2021
  2. FENG JL, Dixon-Suen SC, Jordan SJ, Webb PM, et al
    Statin use and survival among women with ovarian cancer: an Australian national data-linkage study.
    Br J Cancer. 2021 Jun 16. pii: 10.1038/s41416-021-01460.
    >> Share

    May 2021
  3. XU X, Wang Y, Bryce NS, Tang K, et al
    Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents.
    Br J Cancer. 2021 May 12. pii: 10.1038/s41416-021-01420.
    >> Share

    April 2021
  4. TIN TIN S, Reeves GK, Key TJ
    Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank.
    Br J Cancer. 2021 Apr 16. pii: 10.1038/s41416-021-01392.
    >> Share

  5. BIZZARRI N, Pedone Anchora L, Zannoni GF, Carbone V, et al
    Validation of tumour-free distance as novel prognostic marker in early-stage cervical cancer: a retrospective, single-centre, cohort study.
    Br J Cancer. 2021 Apr 14. pii: 10.1038/s41416-021-01384.
    >> Share

  6. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    >> Share

    March 2021
  7. LEPAGE CC, Palmer MCL, Farrell AC, Neudorf NM, et al
    Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer.
    Br J Cancer. 2021 Mar 17. pii: 10.1038/s41416-021-01317.
    >> Share

  8. ZHANG X, Ling MT, Feng H, Wong YC, et al
    Retraction Note to: Id-1 stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01322.
    >> Share

  9. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
    The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
    >> Share

  10. SARINK D, Wilkens LR, White KK, Le Marchand L, et al
    Racial/ethnic differences in anthropometric and hormone-related factors and endometrial cancer risk: the Multiethnic Cohort Study.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01292.
    >> Share

  11. HALLE MK, Sodal M, Forsse D, Engerud H, et al
    A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01305.
    >> Share

    February 2021
  12. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    >> Share

  13. CASTANON A, Rebolj M, Pesola F, Sasieni P, et al
    Recovery strategies following COVID-19 disruption to cervical cancer screening and their impact on excess diagnoses.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01275.
    >> Share

  14. HAYASHI T, Konishi I
    Correlation of anti-tumour drug resistance with epigenetic regulation.
    Br J Cancer. 2021;124:681-682.
    >> Share

  15. LITWIN TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, et al
    Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis.
    Br J Cancer. 2021;124:831-841.
    >> Share

    January 2021
  16. SESTAK I, Blake G, Patel R, Cuzick J, et al
    Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial.
    Br J Cancer. 2021 Jan 22. pii: 10.1038/s41416-020-01228.
    >> Share

  17. LU H, Cunnea P, Nixon K, Rinne N, et al
    Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
    Br J Cancer. 2021 Jan 21. pii: 10.1038/s41416-020-01252.
    >> Share

  18. BRAGA A, Elias KM, Horowitz NS, Berkowitz RS, et al
    When less is more: regarding the use of chest X-ray instead of computed tomography in screening for pulmonary metastasis in postmolar gestational trophoblastic neoplasia.
    Br J Cancer. 2021 Jan 8. pii: 10.1038/s41416-020-01209.
    >> Share

  19. SALAS-BENITO D, Conde E, Tamayo-Uria I, Mancheno U, et al
    The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes.
    Br J Cancer. 2021 Jan 5. pii: 10.1038/s41416-020-01218.
    >> Share

  20. WINFIELD JM, Wakefield JC, Brenton JD, AbdulJabbar K, et al
    Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01217.
    >> Share

    December 2020
  21. PARKER VL, Winter MC, Whitby E, Parker WAE, et al
    Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia.
    Br J Cancer. 2020 Dec 16. pii: 10.1038/s41416-020-01206.
    >> Share

  22. CIBULA D, Slama J, Dostalek L, Fischerova D, et al
    Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery.
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01204.
    >> Share

  23. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    >> Share

    November 2020
  24. KAMAL M, Lameiras S, Deloger M, Morel A, et al
    Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01153.
    >> Share

  25. YAN S, Xuan J, Brajanovski N, Tancock MRC, et al
    The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
    Br J Cancer. 2020 Nov 11. pii: 10.1038/s41416-020-01158.
    >> Share

  26. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    >> Share

    October 2020
  27. MILLINGTON K, Hayes K, Pilcher S, Roberts S, et al
    A serous borderline ovarian tumour in a transgender male adolescent.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01129.
    >> Share

  28. ZHANG Y, Yu M, Jing Y, Cheng J, et al
    Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01123.
    >> Share

  29. ARROYO MUHR LS, Lagheden C, Lei J, Eklund C, et al
    Deep sequencing detects human papillomavirus (HPV) in cervical cancers negative for HPV by PCR.
    Br J Cancer. 2020 Oct 6. pii: 10.1038/s41416-020-01111.
    >> Share

    September 2020
  30. KIM HS, Park SY, Park CY, Kim YT, et al
    A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.
    Br J Cancer. 2020 Sep 30. pii: 10.1038/s41416-020-01098.
    >> Share

  31. VOSS MH, Gordon MS, Mita M, Rini B, et al
    Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
    Br J Cancer. 2020 Sep 11. pii: 10.1038/s41416-020-01041.
    >> Share

  32. MO XT, Leung TH, Tang HW, Siu MK, et al
    CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
    Br J Cancer. 2020;123:833-843.
    >> Share

    August 2020
  33. PHELPS DL, Saso S, Ghaem-Maghami S
    Is ovarian cancer surgery stuck in the dark ages?: a commentary piece reviewing surgical technologies.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01035.
    >> Share

  34. YANG M, Zhang G, Wang Y, He M, et al
    Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer.
    Br J Cancer. 2020 Aug 11. pii: 10.1038/s41416-020-1026.
    >> Share

  35. KYRGIOU M, Arbyn M, Bergeron C, Bosch FX, et al
    Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC).
    Br J Cancer. 2020;123:510-517.
    >> Share

    July 2020
  36. O'MARA TA, Crosbie EJ
    Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0959.
    >> Share

  37. METCALFE KA, Price MA, Mansfield C, Hallett DC, et al
    Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis.
    Br J Cancer. 2020;123:268-274.
    >> Share

    June 2020
  38. MARTINS FC, Couturier DL, Paterson A, Karnezis AN, et al
    Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.
    Br J Cancer. 2020 Jun 18. pii: 10.1038/s41416-020-0900.
    >> Share

  39. VAN WEELDEN WJ, van der Putten LJM, Inda MA, van Brussel A, et al
    Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0925.
    >> Share

    May 2020
  40. JIANG YX, Siu MK, Wang JJ, Mo XT, et al
    Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-kappaB/IL-8 signalling in ovarian cancer.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0865.
    >> Share

  41. BOCHNER F, Fellus-Alyagor L, Ketter D, Golani O, et al
    Bimodal magnetic resonance and optical imaging of extracellular matrix remodelling by orthotopic ovarian tumours.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0878.
    >> Share

  42. FORD CE, Werner B, Hacker NF, Warton K, et al
    The untapped potential of ascites in ovarian cancer research and treatment.
    Br J Cancer. 2020 May 8. pii: 10.1038/s41416-020-0875.
    >> Share

  43. LEI J, Ploner A, Lehtinen M, Sparen P, et al
    Impact of HPV vaccination on cervical screening performance: a population-based cohort study.
    Br J Cancer. 2020 May 4. pii: 10.1038/s41416-020-0850.
    >> Share

    April 2020
  44. SKOLD C, Bjorge T, Ekbom A, Engeland A, et al
    Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0849.
    >> Share

  45. JEDY-AGBA E, Joko WY, Liu B, Buziba NG, et al
    Trends in cervical cancer incidence in sub-Saharan Africa.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0831.
    >> Share

  46. MONTFORT A, Owen S, Piskorz AM, Supernat A, et al
    Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.
    Br J Cancer. 2020 Apr 6. pii: 10.1038/s41416-020-0822.
    >> Share

  47. ZHAO Y, He M, Cui L, Gao M, et al
    Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0825.
    >> Share

  48. HASHIM D, Engesaeter B, Baadstrand Skare G, Castle PE, et al
    Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0790.
    >> Share

  49. ARBYN M, Rezhake R, Yuill S, Canfell K, et al
    Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence.
    Br J Cancer. 2020 Apr 3. pii: 10.1038/s41416-020-0787.
    >> Share

    March 2020
  50. JEON KH, Shin DW, Han K, Kim D, et al
    Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0789.
    >> Share

    February 2020
  51. MASOODI T, Siraj S, Siraj AK, Azam S, et al
    Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Br J Cancer. 2020 Feb 26. pii: 10.1038/s41416-020-0763.
    >> Share

  52. BERG HF, Ju Z, Myrvold M, Fasmer KE, et al
    Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0745.
    >> Share

  53. ROBERTS C, Strauss VY, Kopijasz S, Gourley C, et al
    Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
    Br J Cancer. 2020;122:483-490.
    >> Share

    January 2020
  54. HASEGAWA K, Shimada M, Takeuchi S, Fujiwara H, et al
    A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
    Br J Cancer. 2020 Jan 31. pii: 10.1038/s41416-020-0734.
    >> Share

  55. WHITWELL HJ, Worthington J, Blyuss O, Gentry-Maharaj A, et al
    Improved early detection of ovarian cancer using longitudinal multimarker models.
    Br J Cancer. 2020 Jan 15. pii: 10.1038/s41416-019-0718.
    >> Share

  56. HORIKAWA N, Abiko K, Matsumura N, Baba T, et al
    Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0725.
    >> Share

  57. LIU N, Lin X, Huang C
    Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
    Br J Cancer. 2020;122:279-292.
    >> Share

    December 2019
  58. GENESTIE C, Blanc-Durand F, Auguste A, Pautier P, et al
    Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.
    Br J Cancer. 2019 Dec 17. pii: 10.1038/s41416-019-0687.
    >> Share

  59. SIVALINGAM VN, Latif A, Kitson S, McVey R, et al
    Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0627.
    >> Share

  60. BENGTSEN MB, Veres K, Norgaard M
    First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
    Br J Cancer. 2019 Dec 6. pii: 10.1038/s41416-019-0668.
    >> Share

    November 2019
  61. TUNA M, Ju Z, Yoshihara K, Amos CI, et al
    Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
    Br J Cancer. 2019 Nov 29. pii: 10.1038/s41416-019-0654.
    >> Share

  62. ANNETT S, Moore G, Short A, Marshall A, et al
    FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer.
    Br J Cancer. 2019 Nov 27. pii: 10.1038/s41416-019-0649.
    >> Share

    October 2019
  63. HAMESTER F, Legler K, Wichert B, Kelle N, et al
    Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.
    Br J Cancer. 2019 Oct 29. pii: 10.1038/s41416-019-0607.
    >> Share

    September 2019
  64. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    >> Share

  65. COLOMBO N, Zaccarelli E, Baldoni A, Frezzini S, et al
    Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2019 Sep 20. pii: 10.1038/s41416-019-0584.
    >> Share

    August 2019
  66. TASSI RA, Gambino A, Ardighieri L, Bignotti E, et al
    FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.
    Br J Cancer. 2019 Aug 22. pii: 10.1038/s41416-019-0553.
    >> Share

  67. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Correction: Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Aug 9. pii: 10.1038/s41416-019-0545.
    >> Share

  68. RUSSELL MR, Graham C, D'Amato A, Gentry-Maharaj A, et al
    Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0544.
    >> Share

  69. SHI T, Jiang R, Pu H, Yang H, et al
    Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study.
    Br J Cancer. 2019 Aug 6. pii: 10.1038/s41416-019-0543.
    >> Share

    July 2019
  70. LEVASSEUR N, Chia S
    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?
    Br J Cancer. 2019;121:1-2.
    >> Share

  71. BERNDSEN RH, Castrogiovanni C, Weiss A, Rausch M, et al
    Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression.
    Br J Cancer. 2019;121:139-149.
    >> Share

    June 2019
  72. LECAVALIER-BARSOUM M, Chaudary N, Han K, Pintilie M, et al
    Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
    Br J Cancer. 2019 Jun 26. pii: 10.1038/s41416-019-0497.
    >> Share

  73. QIAN F, Rookus MA, Leslie G, Risch HA, et al
    Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers.
    Br J Cancer. 2019 Jun 19. pii: 10.1038/s41416-019-0492.
    >> Share

  74. PLUMMER C, Michael A, Shaikh G, Stewart M, et al
    Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
    Br J Cancer. 2019 Jun 11. pii: 10.1038/s41416-019-0481.
    >> Share

    April 2019
  75. REIJNEN C, van Weelden WJ, Arts MSJP, Peters JP, et al
    Poor outcome in hypoxic endometrial carcinoma is related to vascular density.
    Br J Cancer. 2019 Apr 23. pii: 10.1038/s41416-019-0461.
    >> Share

  76. HORN J, Denecke A, Luyten A, Rothe B, et al
    Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
    Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0453.
    >> Share

    March 2019
  77. FORTNER RT, Terry KL, Bender N, Brenner N, et al
    Sexually transmitted infections and risk of epithelial ovarian cancer: results from the Nurses' Health Studies.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0422.
    >> Share

  78. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Mar 19. pii: 10.1038/s41416-019-0425.
    >> Share

  79. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0433.
    >> Share

    February 2019
  80. FROELING FEM, Ramaswami R, Papanastasopoulos P, Kaur B, et al
    Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
    Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0402.
    >> Share

  81. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    >> Share

    January 2019
  82. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    >> Share

  83. MULATI K, Hamanishi J, Matsumura N, Chamoto K, et al
    VISTA expressed in tumour cells regulates T cell function.
    Br J Cancer. 2019;120:115-127.
    >> Share

    December 2018
  84. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    >> Share

    November 2018
  85. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
    Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
    >> Share

  86. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    >> Share

    October 2018
  87. WORTMAN BG, Creutzberg CL, Putter H, Jurgenliemk-Schulz IM, et al
    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
    Br J Cancer. 2018 Oct 25. pii: 10.1038/s41416-018-0310.
    >> Share

  88. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    >> Share

  89. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    >> Share

  90. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0311.
    >> Share

  91. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    >> Share

  92. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    >> Share

  93. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    >> Share

  94. WILLIAMS LA, Mills L, Hooten AJ, Langer E, et al
    Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0277.
    >> Share

    August 2018
  95. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    >> Share

  96. AOKI Y, Ochiai K, Lim S, Aoki D, et al
    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0206.
    >> Share

    July 2018
  97. GADDUCCI A, Grosso F, Scambia G, Raspagliesi F, et al
    A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0190.
    >> Share

  98. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    >> Share

  99. KOMMOSS FK, Karnezis AN, Kommoss F, Talhouk A, et al
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Br J Cancer. 2018 Jul 27. pii: 10.1038/s41416-018-0187.
    >> Share

  100. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    >> Share

  101. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    >> Share

  102. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    >> Share

    June 2018
  103. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    >> Share

  104. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    >> Share

  105. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
    Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
    >> Share

  106. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    >> Share

  107. TUNG NM, Garber JE
    BRCA1/2 testing: therapeutic implications for breast cancer management.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0127.
    >> Share

    May 2018
  108. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
    Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
    >> Share

  109. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    >> Share

    March 2018
  110. LAGHEDEN C, Eklund C, Lamin H, Kleppe SN, et al
    Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0053.
    >> Share

  111. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    >> Share

  112. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    >> Share

    February 2018
  113. GUSTAVSSON I, Aarnio R, Berggrund M, Hedlund-Lindberg J, et al
    Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology.
    Br J Cancer. 2018 Feb 13. pii: bjc2017485. doi: 10.1038/bjc.2017.
    >> Share

  114. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    >> Share

    January 2018
  115. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    >> Share

  116. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    >> Share

  117. LAM JUH, Elfstrom KM, Ejegod DM, Pedersen H, et al
    High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
    Br J Cancer. 2018;118:138-144.
    >> Share

    December 2017
  118. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
    Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
    >> Share

    November 2017
  119. SEAMON LG, Java JJ, Monk BJ, Penson RT, et al
    Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
    Br J Cancer. 2017 Nov 28. pii: bjc2017400. doi: 10.1038/bjc.2017.
    >> Share

  120. HALLE MK, Tangen IL, Berg HF, Hoivik EA, et al
    HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    >> Share

  121. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    >> Share

  122. MARKOVINA S, Wang S, Henke LE, Luke CJ, et al
    Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
    Br J Cancer. 2017 Nov 7. doi: 10.1038/bjc.2017.
    >> Share

    October 2017
  123. HEINONEN HR, Mehine M, Makinen N, Pasanen A, et al
    Global metabolomic profiling of uterine leiomyomas.
    Br J Cancer. 2017 Oct 26. doi: 10.1038/bjc.2017.
    >> Share

  124. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    >> Share

    September 2017
  125. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    >> Share

  126. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    >> Share

  127. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    >> Share

    August 2017
  128. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    >> Share

  129. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    >> Share

  130. BURGER EA, Pedersen K, Sy S, Kristiansen IS, et al
    Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016